These findings support the proposed use of CDC42 inhibitors or alternative pathway interventions in combination with chemotherapy for improved patient treatments, as suggested for several other cancer types [45], though no known clinical trials for this combination therapy currently exist. This evidence concerns the gene CDC42 and cancer.